PRESS RELEASES

CATCH UP WITH OUR LATEST PRESS RELEASES

Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

THOUSAND OAKS, Calif., February 21, 2024 -- Capsida Biotherapeutics (“Capsida”)…

Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies

Strategic partnership leverages Capsida’s next-generation manufacturing…

Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa

THOUSAND OAKS, Calif., September 20, 2023 -- Capsida Biotherapeutics (“Capsida”)…

Capsida Biotherapeutics Announces Publication in Nature Nanotechnology Identifying Novel Capsid With Significantly Increased Brain Transduction

Foundational research by Capsida and Caltech demonstrates ability to engineer AAVs…

Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer

Industry veteran added to complement co-founders Nicholas Flytzanis, Ph.D. and Nick…

AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need

Partnership Combines AbbVie's extensive capabilities with Capsida's novel…

Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer

Hakim brings more than 25 years’ experience leading finance and exponential growth…

Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40

Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues…

Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief Operating Officer

Company creates chief operating officer role and appoints veteran manufacturing and…

PharmaVoice profiles Capsida CEO Peter Anastasiou

Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality…

Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO

Longtime industry executive Peter Anastasiou appointed Chief Executive Officer…

Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference

Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a…

Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing

New 15,000 square-foot facility in Thousand Oaks will enable industry leading…

Capsida Appoints Swati Tole, M.D., as Chief Medical Officer

Clinical development leader will help advance Capsida’s breakthrough AAV gene…

Capsida Biotherapeutics Debuts with $140 Million of Capital

Versant, Westlake Village BioPartners launch next-generation gene therapy company…